This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

EYLEA® (aflibercept) 8 mg

Early Insights Case Study Webinar Series

Close-up-eye

Welcome to our Early Insights webinar series where key experts in medical retina, from both the UK and the US, discuss their patient cases and experience treating neovascular age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO) with EYLEA® (aflibercept) 8 mg.

 

Meet our expert speakers for this webinar series:

Richard Gale

Professor of Ophthalmology at York University and Honorary Consultant Ophthalmologist at Scarborough Teaching Hospitals NHS Foundation Trust

Serena Salvatore

Consultant Ophthalmologist at University Hospitals Bristol and Weston NHS Foundation Trust

Michael Stewart

Chairman of Ophthalmology at Mayo Clinic, US

John Kitchens

MD, Vitreoretinal Surgeon at Retina Associates of Kentucky, USA

Early Insights Case Study Webinar 2

Treating nAMD and DMO patients in clinical practice

Join Richard Gale, Serena Salvatore and John Kitchens in this recording of our second EYLEA 8 mg Early Insights webinar. Tune in as they share their patient cases and experience treating neovascular age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO) with EYLEA 8 mg in their practices in both the UK and US.

Prescribing information for EYLEA® (aflibercept) can be found here.

Early Insights Case Study Webinar 1

Initiating nAMD and DMO patients in clinical practice

Join our expert panelists as they share and compare clinical experiences of commencing patients and treating neovascular age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO) with case studies from both the US and the UK.


Early experience of aflibercept 8 mg in UK clinical practice

In this webinar session, Professor Richard Gale presents case studies from his clinic, providing insight into commencing eligible nAMD and DMO patients with EYLEA 8 mg. Professor Gale discusses his experience injecting the higher dose and initial treatment responses in relation to vision, fluid and safety profile.

 

Prescribing information for EYLEA® (aflibercept) can be found here.

EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2321, September 2024
HCP Resources
Access useful, downloadable ophthalmology resources for HCPs
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg

PP-EYL-GB-2577 | November 2024